Announcement PDF ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 28 August 2025 Companies Announcements Office Australian Securities Exchange 2025 Annual Report ImpediMed Limited (ASX:IPD) is pleased to release its Annual Report for the financial year ended 30 June 2025. Approved for release by the Board of ImpediMed Limited. For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au Transforming Patient-Centred Care AnnualReport 2025 impedimed.com 01 Overview ImpediMed is a leading global medical technology company that manufactures and sells innovative medical devices employing bioimpedance spectroscopy (BIS) technology. These devices are used for the non-invasive clinical assessment and monitoring of fluid status and tissue composition in patients. ImpediMed is primarily addressing the significant challenges and burdens of secondary lymphoedema, with a particular focus on breast cancer-related lymphoedema (BCRL). Through the SOZO® Digital Health Platform and L-Dex®, ImpediMed offers the only FDA-cleared technology utilising BIS, becoming the standard of care for the early detection and management of BCRL. Our commitment is to address significant unmet patient needs in breast cancer-related lymphoedema and cancer-related lymphoedema, improving cancer survivorship through innovation in the design and delivery of fluid and body composition analytics. Our Board and Executive Leadership team are leading a refined strategy focused on sales execution and customer-centric innovation. Our mission: To improve patient outcomes by setting new standards of care in fluid and body composition management. Contents 01 03 04 06 09 13 15 16 18 24 39 40 81 82 83 87 89 90 Overview Message from the Chair Message from the CEO SOZO® Digital Health Platform Operating and financial review Environmental, Social and Governance Board of Directors Executives Directors’ report Remuneration report Auditor's independence declaration Financial statements Consolidated entity disclosure statement Directors' declaration Independent auditor's report Shareholder information Glossary Corporate directory 02 Platform Technology Transforming Patient-Centred Care SOZO® Core Business quarterly Total Contract Value (TCV) 6.3 4.9 4.8 3.4 3.2 $A millions 2.2 FY24 Q3 FY24 Q4 FY25 Q1 FY25 Q2 FY25 Q3 FY25 Q4 03 Message from the Chair Christine Emmanuel-Donnelly Chair of the Board On behalf of the Board of Directors and Management, I am pleased to present the Annual Report for ImpediMed Limited for the 2025 financial year. Thank you to our shareholders for your continued support. I am extremely proud of the management team and staff who have put patients first, focusing on preventing the development of the painful condition of secondary lymphoedema in breast cancer survivors. At the same time, executing on the commercial opportunities available to the Company for the benefit of our shareholders. Revenue growth of 23% from last year is encouraging. With reimbursement steadily increasing to 82%, together with increased investment in our sales capability, we forecast further acceleration in growth. This momentum is strengthened by the recruitment of Scott Long, as our new Senior Vice President of Sales. In parallel, the team has continued to advance the strategic direction set in 2024. We successfully completed an observational trial in the heart failure application and commenced commercial execution of our body composition offering. Increased investment in product development is supported by the recruitment of Scott Savage, new Chief Product Officer. These initiatives are being delivered while reducing overall cash cost base by 16% underpinned by a deliberate refresh of the team skill set. In February 2025, ImpediMed secured a capital injection via a loan facility that supports its growth and commercialisation activities as it executes on the opportunity and path to profitability. This provides confidence to our CEO and refreshed executive team, who are committed to balancing innovation, growth, and prudent financial management. I would like to acknowledge my fellow directors, whose expertise and growth mindset provide valuable guidance in balancing risk and opportunity. The 2025 financial year represents our first full cycle under this renewed strategy, and I am encouraged by both the progress made and the momentum for the year ahead. On behalf of the Board, I would like to thank our ImpediMed employees whose passion for bringing the benefits of bioimpedance spectroscopy to breast cancer survivors—and determination to expand its application across ImpediMed’s SOZO® Digital Health Platform—continues to inspire and drive our shared success. Sincerely Christine Emmanuel-Donnelly Chair 04 Message from the CEO Dr Parmjot Bains Managing Director and CEO At the heart of everything we do at ImpediMed is the patient For someone recovering from cancer, survivorship is not just about remission—it’s about living well. Yet too often, secondary lymphoedema emerges silently in 1 in 5 breast cancer patients1, reducing quality of life, and increasing healthcare burden and costs. Other cancer patients face unplanned weight loss or muscle loss during treatment, lowering survivorship rates. Clinicians, despite their best efforts, are limited by reactive tools and fragmented data. SOZO® is changing that... Our digital health platform empowers clinicians to monitor cancer survivors with precision, enabling early detection of lymphoedema and tracking changes in muscle mass and hydration. These insights support clinical decisions around early detection and prevention of chronic lymphoedema, exercise, nutrition, and recovery—key components of survivorship. With SOZO, we’re not only improving outcomes, we are forging new standards of care. This year, we were proud to see many more leading U.S. healthcare systems adopt SOZO as part of their standard cancer survivorship programs. These systems are not only improving patient care—they are building scalable, reimbursed programs that align clinical, operational, and financial value. This progress reaffirms our vision: To revolutionise patient care with fluid and body composition algorithms, enhancing health outcomes through clinically validated, secure platform technology. Extending impact: Heart Failure and Body Composition management While our leadership in cancer survivorship continues to grow, FY25 also marked the strategic extension of SOZO into cardiac care and planned weight management. We introduced SOZO Pro, our next-generation platform designed to support advanced fluid and body composition monitoring across broader clinical settings. This expansion was underpinned by the successful completion of a 116-patient investigator-initiated observational trial in heart failure, demonstrating SOZO’s potential to support fluid status monitoring in this high-burden population. We also appointed a dedicated heart failure product lead to guide commercial and clinical execution in this space. At the same time, we advanced our work in planned and unplanned weight loss, with a particular focus on measuring muscle and fat mass—using SOZO’s FDA-cleared, non-invasive measurement to provide clinicians with objective, reliable data to personalise nutrition, exercise, and care planning in alignment with emerging clinical practice guidelines. These developments reflect the scalability of our platform and the value of our core technology across multiple disease states. A clear strategy, executed with discipline FY2025 marked a year of disciplined focus and strong foundational execution. With our new strategy defined in February 2024, we targeted the U.S. breast cancer-related lymphoedema (BCRL) market, prioritising lead generation, sales execution, and customer-facing investments. We ended the year with a record number of SOZO devices sold in the U.S. and 82% of the population now covered by insurance for SOZO use—up from 140 million to 286 million covered lives. This growth is a result of both commercial efforts and ongoing clinical validation, including strong endorsement from NCCN Guidelines and the National Accreditation Program for Breast Centres, which are now supporting routine lymphoedema screening. 1. Letellier, ME., Ibrahim, M., Towers, A. et al. Incidence of lymphedema related to various cancers. Med Oncol 41, 245 (2024). 05 Message from the CEO FY 2025 showed encouraging momentum from our focus on front line sales execution: • 48% of ImpediMed team is focused towards front line execution • 60% growth in SOZO® opportunity pipeline versus FY24 • 23% revenue growth vs FY24 • 15% increase in patient measurements. FY25 total revenue was $12.7 million, with SOZO-Core business revenue growing 25% year-on-year to $12.1 million. During the year, we took prudent steps to improve working capital efficiency. In Q4 FY24, we implemented measures to reduce our cash burn. As a result, FY25 operating cash expenditure was 16% lower than FY24, compared with our original forecast of a 10% reduction. The majority of the reduction was from senior management remuneration. A world-class leadership team to drive growth FY25 marked the first full year with a revitalised Executive Team. During the year, we welcomed: • Scott Savage as Chief Product Officer • Scott Long as Senior VP of Sales • Mike Bassett as Head of Business Development and Investor Relations. Together, our leadership team brings deep expertise from global leaders including Pfizer, Nanosonics, Google, and Becton Dickinson, as well as decades of experience in U.S. breast cancer care, sales, marketing, and digital health. Our Board also continues to play a critical role in steering strategy, strengthening governance, and supporting our mission. With our Board comprising 67% females and a diverse Executive Team (40% female, 60% male), we are proud to lead with inclusion and innovation. Committed to our Mission, guided by our Values At ImpediMed, our Mission is clear: To improve patient outcomes by setting new standards of care in fluid and body composition management. We are guided by customer-centric innovation, grounded in integrity, and committed to excellence and accountability. Our Values shape not only how we serve patients and clinicians — but how we empower our people to grow and lead with purpose. Looking ahead In FY2026, we will continue to execute with focus. Our priorities are clear: • Accelerate revenue growth through strong sales performance in BCRL • Expand reimbursement coverage and clinical adoption • Deliver new commercial and clinical milestones in heart failure and body composition • Profitability through revenue growth and financial discipline. With a growing pipeline, expanding reimbursement, and the right team in place, we are confident in our trajectory. To our employees—thank you for your passion and purpose. To our clinicians and patients—you are our North Star. To our shareholders—thank you for your continued support as we deliver impact, innovation, and long-term value. Thank you for being part of our journey. Dr Parmjot Bains Managing Director and CEO 06 Transforming cancer survivorship: A patient-centred approach with SOZO® For many breast cancer survivors, completing treatment does not mark the end of their health journey. Up to 1 in 5 women will go on to develop secondary lymphoedema—a painful, chronic condition that can dramatically impact quality of life. Others face muscle wasting, fatigue, and a heightened risk of recurrence without effective tools to track and manage body composition. Patients often lack early warning systems and clinicians struggle with limited and imprecise tools. Designed to meet the unmet needs of survivorship care, SOZO is a non-invasive, FDA-cleared, and reimbursed digital health platform that enables clinicians to detect subclinical lymphoedema before symptoms appear, monitor muscle mass and hydration, and promote exercise-based recovery programs. From a single 30-second scan, clinicians gain precise, actionable data that supports proactive, personalised care—empowering survivors to regain strength, confidence, and control over their health. One device. Multiple FDA-cleared applications. Proven outcomes. A single SOZO measurement provides: L-Dex® lymphoedema analysis HF-DexTM heart failure analysis BodyCompTM analysis Hy-Dex® hydration analysis One solution, multiple regulatory authority cleared applications Lymphoedema - FDA clearance, CE Mark Body composition - FDA clearance, CE Mark Heart failure - FDA clearance, CE Mark Protein calorie malnutrition - FDA clearance, CE Mark The world’s most advanced non-invasive bioimpedance spectroscopy (BIS) system SOZO, utilising cutting-edge bioimpedance spectroscopy (BIS) technology, delivers a comprehensive snapshot of fluid status and tissue composition in under 30 seconds. ImpediMed’s proprietary technology sends 256 unique frequencies through the body to assess both intra and extracellular fluid. This precise detection of fluid changes aids healthcare providers in managing chronic diseases and offers individuals personalised insights for health and wellness management. BIS provides highly accurate indicators for routine monitoring and patient health management. 07 Results are instantly available at the point of care through cloud-based software, allowing for aggregation and trending across the healthcare system. This FDA-cleared, CE-marked, and ARTG-listed digital health platform supports early detection of secondary lymphoedema, monitors fluid status in heart failure patients, and aids in overall health maintenance from a single measurement. Actionable Aggregates and trends patient data for actionable insights Quick 30-second, non-invasive test Scalable Patient data accessible by care teams across the health system Secure Controlled access to the HITRUST certified SOZO network with unique security settings Strong adoption and validated technology ImpediMed is a global provider of medical technology for measuring, monitoring, and managing tissue composition using BIS. Revenue is generated through the system sale of medical devices and subscription services for the SOZO® platform technology. In the U.S., a direct sales force focuses on SOZO health system contracts, while independent distributors manage sales outside the U.S. 1,100+ THE UNIVERSITY OF TEXAS SOZO Systems placed globally 1,100,000+ patient tests San Diego’s Health Care Leader WEXNER MEDICAL CENTER 08 Clinical practice guidelines support BIS In May 2025, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship reaffirmed BIS as the recommended tool for screening at-risk cancer patients for early signs of lymphoedema, and further emphasised recommendation for pre-operative baseline measurement to help prevent misdiagnosis. ImpediMed, with its SOZO® Digital Health Platform and L-Dex®, remains the sole provider of FDA-cleared BIS technology for lymphoedema assessment. The guidelines advocate regular screening for cancer survivors at risk. Standards point to these clinical practice guidelines for breast centre accreditation In September 2024, the American College of Surgeons National Accreditation Program for Breast Centres (NAPBC) released Accreditation Standards for Survivorship, recommending use of evidence-based guidelines to implement protocols for survivorship, which can include a lymphedema prevention program for regular symptom assessment and clinical evaluation using bioimpedance spectroscopy. Guidelines support subclinical detection, intervention and BIS National Comprehensive Cancer Network® (NCCN®) For patients and survivors at risk for lymphoedema: • Recommends pretreatment baseline objective measurements be obtained using validated tools that measure extracellular fluid, such as bioimpedance spectroscopy. • Recommends regular lymphoedema screening for lymphedema by validated tools that measure extracellular fluid, such as bioimpedance spectroscopy1 American Society of Breast Surgeons For breast cancer patients: • Recommends prospective surveillance • Recommends baseline and follow-up measurements International Society of Lymphology (ISL) For cancer patients at risk for lymphoedema: • Recommends prospective surveillance • Recommends bioimpedance spectroscopy (BIS) as an option for early detection Multinational Association of Supportive Care in Cancer For cancer patients at risk for lymphoedema: • Recommends prospective surveillance • Recommends bioimpedance spectroscopy (BIS) as an option for early detection American Physical Therapy Association For breast cancer patients: • Recommends prospective surveillance • Recommends monitoring with BIS For diagnosis of upper quadrant lymphoedema: • Recommends L-Dex to detect subclinical lymphoedema 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed June 3, 2025. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. American College of Surgeons National Accreditation Program for Breast Centers (NAPBC) Optimal Resources for Breast Care 2024 Standards, updated September 2024. Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American College of Surgeons. Content does not reflect the views or interpretations of the American College of Surgeons. McLaughlin SA, et al. Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel. ASO 2017;DOI 10.1245/s10434-017-5982-4. The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology. Lymphology. 2020;53:3-19. Wong HC, et al., Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention of breast cancer-related arm lymphedema (BCRAL): international Delphi consensus-based recommendations. eClinicalMedicine 2024;68:102441. Davies C, et al. Interventions for Breast Cancer–Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA. Physical Therapy 2020;100(7):1-17. Levenhagen K, et al. Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association. Physical Therapy 2017;97(7):729-45. Armer J, et al. ONS Guidelines™ for Cancer. Treatment-Related Lymphedema. Oncology Nursing Forum 2020;47(5):518-38. LE&RN Centers of Excellence Program Description and Link to Online Application.https://lymphaticnetwork.org/documents/CoE_Program_Descrition_and_Link_to_On line_Application.pdf. Accessed August 6, 2021. National Lymphedema Network Position Statement: The Diagnosis and Treatment of Lymphedema. February 2011. Oncology Nursing Society For patients who have had cancer-related surgery: • Recommends prospective surveillance • Recommends lymphoedema education Lymphatic Education & Research Network Center of Excellence Program • Requires risk assessment using perometry or bioimpedance spectroscopy National Lymphedema Network • BIS provides reliable data and can detect early changes associated with lymphoedema 09 Operating and financial review Continued momentum with private payors Since June 2023, ImpediMed has secured coverage for over 286 million lives in the U.S., doubling the number of covered lives in the past twelve months. This includes eight of the top ten private payors and several regional payors. During the year the number of states with coverage above 80% increased from 16 to 36 and of these 21 states have coverage above 90%. Expanded customer footprint – poised for growth With continued increase in payor coverage supported by clinical practice guidelines and accreditation standards, ImpediMed is seeing growth in adoption of SOZO® by health systems. The growth was evident in Q4 FY25 with expansion into a number of large Integrated Delivery Networks (IDNs) along with sales to new customers and renewals of existing contracts. During Q4 FY25, expansions into key IDNs included: • 9-unit contract with Legacy Health, a six hospital health system serving the Pacific Northwest region • Leading healthcare centres added and renewed in the quarter include: Yale New Haven, University of Texas MD Anderson, Memorial Sloane Kettering, Mount Sinai Medical Centre, Corewell Health, Ascension, Northwell, University of Virginia, University of North Carolina, Kansas University, University of Tennessee and University of Miami. With a strong presence in top-tier customers, including 23 of 33 NCCN Institutions, 20 of the top 25 IDNs, and over 150 of the top 500 U.S. Cancer Centers, ImpediMed is well-positioned for continued growth. Technology adoption – increased patient testing Since the launch of SOZO, over 1.19 million patient tests have been conducted, with 287,000 in FY25, representing a 15% year-over-year increase. Q4 FY25 saw a record 74,000 tests, a 9% increase compared with the same quarter of the previous year. This patient database, which has grown at a 3-year CAGR of 21%, has enhanced the accuracy of SOZO, automated key protocols, improved algorithms, and provided real-world data for regulatory clearances. SOZO Patient Tests (000s) 21% 300 3-year CAGR1 250 Thousands 200 150 100 50 0 FY18 FY19 1. Compound Annual Growth Rate (based on annual totals) FY20 FY21 FY22 FY23 FY24 FY25 10 Operating and financial review Installed base growth Global installed base grew 14% over the year finishing FY25 with 1,139 SOZO® systems installed. In the U.S., installed base grew in FY25 by 94 units or 19% to 583 units. In FY25 a total of 114 new units were installed, up 68% compared with 68 new units installed in FY24. In Q4 FY25 a total of 44 new units were placed in the U.S., an increase of 100% compared with the previous quarter, demonstrating improved momentum resulting from the emerging impact of the focus on sales and marketing execution. In the Rest of World (ROW) markets, the installed base grew 8% to 556 units, a net increase of 43 units over FY24. The majority of ROW sales were made in Australia via the Company’s distribution partner. Installed Base Units1 GLOBAL Up 14% vs FY24 U.S. REST OF WORLD 1,139 960 57 1,002 56 1,065 80 77 Up 19% vs FY24 Up 8% vs FY24 583 466 32 1H FY24 2H FY24 1H FY25 2H FY25 489 36 523 48 66 1H FY24 2H FY24 1H FY25 2H FY25 Opening IB2 494 25 513 20 542 29 556 14 1H FY24 2H FY24 1H FY25 2H FY25 New devices added 1. The installed base units in 1H FY24 and 2H FY24 were restated during the year to remove inactive units. 2. Net of churn in current quarter (FY24 global churn <3%) Churn = [Number of devices cancelled or not renewed in period] / [Average cumulative device placements in the period]. New market opportunities and development activities ImpediMed is finalising development of a new software release that will further enhance the functionality and user experience of the SOZO Digital Health Platform. SOZO Pro, the next generation of the SOZO system which includes an integrated scale and enables the removal of the contra-indication for patients with pacemakers and implantable defibrillators, was initiated into clinical research use in the heart failure and body composition spaces, under investigator initiated studies, to support the generation of clinical use data. 11 Operating and financial review Global revenue Total revenue in FY25 was $12.7 million, an increase of 23% or $2.4 million compared with FY24. In constant currency1 total revenue was up 22% compared with the previous year. The increase in revenue was mainly due to new SOZO® system sales and recurring revenue growth in the North America market. Significantly, revenue associated with SOZO Core Business2 in FY25 was $12.1 million, up $2.4 million or 25% compared with FY24. Revenue in North America was $11.6 million, an increase of $2.4 million or 26% compared with FY24. Global Revenue by Category 3.4 11.3 10.3 0.5 0.1 $A millions 2.0 0.8 Global Revenue by Geography 12.7 0.6 0.1 11.3 10.3 0.9 0.1 2.0 1.1 $A millions 3.4 Clinical Legacy/other SOZO Unallocated ROW North America 12.7 1.0 0.1 8.5 9.6 12.1 8.3 9.3 11.6 FY23 FY24 FY25 FY23 FY24 FY25 SOZO Core Business Total Contract Value (TCV5) signed in FY25 was $19.2 million, compared with $9.6 million signed in FY24. TCV signed in H2 FY25 was up $3.3 million or 41% compared with H1 FY25. SOZO Core Business ARR SOZO Core Business TCV 10.1 11.0 12.5 11.3 14.0 1H FY24 2H FY24 1H FY25 2H FY25 $A millions $A millions SOZO Core Business Annual Recurring Revenue (ARR3) on contracts was $14.0 million at 30 June 2025, compared with $11.0 million at 30 June 2024. Churn rate4 <3%. 8.0 5.6 4.0 1H FY24 2H FY24 1H FY25 2H FY25 1. Constant currency removes the impact of foreign exchange rate movements to facilitate comparability of operational performance. This is done by converting the current year revenue of entities that use currencies other than Australian dollars at the average rates that were applicable in the prior year. The average exchange rate used for the Company’s major foreign currency (USD) for the year was 0.6459 (2024: 0.6553). 2. SOZO Core Business represents revenue from SOZO contracts in the Oncology/Lymphoedema market and excludes SOZO Clinical Business and legacy device/other revenues. 3. Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognised for the next 12-month period based on existing contracts, assuming installation upon sale and no churn. The exchange rate used for ARR calculation was 0.6434 (2024: 0.6670). 4. Based on SOZO units globally. [Number of units cancelled or not renewed in the period] / [Average cumulative unit placements in the period]. 5. SOZO Core Business Total Contracted Value (TCV) includes any consideration for the sale of SOZO units as well as the total licence fees for the duration of the signed contracts. Typically, these contracts are for a period of three years. 12 Operating and financial review Other financial results Gross margin Gross profit margin was 86% for the year, compared with 87% in FY24. Finance and other income Net finance income for the year was ($0.2) million, a decrease of $1.7 million compared with FY24 driven by interest expense associated with the SWK credit agreement executed in FY25. Total other income for the year was $1.2 million, a decrease of $1.6 million compared with FY24 driven by a non-recurring U.S. Government grant in FY24. Operating expenses Total operating expenses for the year were $35.2 million, an increase of $2.2 million compared with FY24 operating expenses of $33.0 million. Salaries and benefits in FY25 were $20.0 million, a decrease of $1.5 million compared with the salaries and benefits expense in FY24 of $21.5 million. Share-based payments were $1.6 million, $2.3 million higher compared with the credit of $0.7 million in FY24. Together salaries and benefits and share-based payments represent 62% of total operating expenses (FY24: 63%). Administration expenses were $3.2 million for the year, consistent with FY24. Depreciation and amortisation expenses were $4.6 million, an increase of $2.3 million compared with FY24. Operating result Net loss from continuing operations was $23.2 million in FY25, compared with $19.8m in FY24. The increased loss was driven by lower finance and grant income, higher share-based payments and higher finance expenses, partially offset by higher gross profit resulting from new SOZO® system sales and recurring revenue growth, and lower salaries and benefits expense. Cash Cash and cash equivalents were $22.2 million at 30 June 2025 compared with $24.6 million at 30 June 2024. Net cash used in operating activities during FY25 was $14.3 million compared with $17.8 million in the prior year. The net cash used in operating activities in the period includes receipts from government grants/tax incentives of $0.9 million compared with $3.4 million in FY24, and interest received of $1.0 million compared with $1.6 million in the prior year. Net cash used in investing activities during FY25 was $1.4 million compared with $3.1 million in FY24. The decrease is primarily related to lower expenditure on the development of SOZO Pro, as this work has been completed. 13 Environmental, Social and Governance CEO Statement Commitment to Patient Outcomes, Sustainability, and Good Governance FY2025 impact and ESG update At ImpediMed, our mission is to improve patient outcomes by forging new standards of care in fluid and body composition management. In FY25, this mission guided our continued commitment to clinical excellence, compliance, sustainability, social responsibility, and strong governance. Our focus remains on the health and well-being of patients. We are revolutionising care with innovative, validated, and guideline-supported technology that delivers meaningful insights across cancer survivorship, heart failure, and weight management. As SOZO® becomes increasingly embedded in oncology care pathways, its ability to transform clinical outcomes and improve lives is becoming more evident. Since SOZO’s launch, more than 1.19 million patient tests have been completed globally, with 287,000 tests conducted in FY25 alone. Over the past three years, patient testing volumes have grown at an average rate of 21% annually, reflecting growing demand for proactive, data-